Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1602720

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1602720

Amyotrophic Lateral Sclerosis Treatment Market by Treatment (Medication, Stem Cell Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030

PUBLISHED:
PAGES: 197 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 734.42 million in 2023, expected to reach USD 790.52 million in 2024, and is projected to grow at a CAGR of 7.73%, to USD 1,237.05 million by 2030.

Amyotrophic Lateral Sclerosis (ALS) treatment market research encompasses a comprehensive analysis of various therapeutic solutions aimed at managing ALS symptoms, slowing disease progression, and improving patient quality of life. The necessity for ALS treatments is underscored by the severe nature of the disease, which currently lacks a definitive cure, prompting a critical demand for innovative therapies. Treatments typically include the use of neuroprotective drugs, physical therapies, and emerging multidisciplinary approaches that involve genetic and stem cell research. The market is influenced by factors such as advancements in biotechnology, increased funding for neurological research, and an aging population that elevates the prevalence of ALS cases. Key growth opportunities lie in personalized medicine and gene therapy, areas that can be leveraged through strategic partnerships between biotech firms and research institutions. Companies should also consider geographic diversification, tapping into underexplored markets in Asia and South America, where rising healthcare infrastructure and awareness are fostering a keen interest in innovative treatments. However, market growth faces challenges including high R&D costs, stringent regulatory hurdles, and the unpredictable nature of disease progression that complicates treatment efficacy measurement. Intellectual property rights and competition from off-label drugs further constrain the landscape. According to market dynamics, the future of ALS treatment innovation hinges on breakthroughs in CRISPR technologies and biomarker research, which could significantly enhance early detection and therapeutic precision. Stakeholders anticipating growth should heavily invest in scientific collaborations and patient-centric care models to align with the shifting paradigm toward personalized treatment approaches. Understanding market nature indicates that patient advocacy and education will play pivotal roles in reshaping treatment uptake and acceptance. In summary, while navigating regulatory landscapes remains complex, firms that prioritize agility in research and strategic alliances will better position themselves to capture emerging opportunities in the ALS treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 734.42 million
Estimated Year [2024] USD 790.52 million
Forecast Year [2030] USD 1,237.05 million
CAGR (%) 7.73%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyotrophic Lateral Sclerosis Treatment Market

The Amyotrophic Lateral Sclerosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant number of amyotrophic lateral sclerosis patients worldwide
    • Growing awareness about ALS treatment among population
  • Market Restraints
    • High cost associated with ALS treatments
  • Market Opportunities
    • Increasing research activities to develop novel ALS drugs and treatments
    • Improved healthcare infrastructure across economies
  • Market Challenges
    • Stringent approval processes for ALS therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Amyotrophic Lateral Sclerosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyotrophic Lateral Sclerosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyotrophic Lateral Sclerosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyotrophic Lateral Sclerosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyotrophic Lateral Sclerosis Treatment Market

A detailed market share analysis in the Amyotrophic Lateral Sclerosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyotrophic Lateral Sclerosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyotrophic Lateral Sclerosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyotrophic Lateral Sclerosis Treatment Market

A strategic analysis of the Amyotrophic Lateral Sclerosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyotrophic Lateral Sclerosis Treatment Market, highlighting leading vendors and their innovative profiles. These include AB Science SA, Amylyx Pharmaceuticals Inc., Aquestive Therapeutics Inc., Ascend Pharmaceuticals LLC, Biogen Inc., Biohaven Pharmaceutical Holding Co Ltd, BrainStorm Cell Limited, Corestem, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche AG, Genervon Biopharmaceuticals, LLC, Hackensack Meridian Health, Inc., Implicit Bioscience Ltd., Ionis Pharmaceuticals, Inc., ITF Pharma, Inc., Kringle Pharma, Inc., Mitsubishi Tanabe Pharma Corporation, Orion Corporation, Orphazyme A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi-Aventis Groupe S.A., Sun Pharmaceutical Industries Ltd, and Treeway B.V..

Market Segmentation & Coverage

This research report categorizes the Amyotrophic Lateral Sclerosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medication and Stem Cell Therapy. The Medication is further studied across Edaravone and Riluzole.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-AD36CD897F1B

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant number of amyotrophic lateral sclerosis patients worldwide
      • 5.1.1.2. Growing awareness about ALS treatment among population
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with ALS treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research activities to develop novel ALS drugs and treatments
      • 5.1.3.2. Improved healthcare infrastructure across economies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval processes for ALS therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Edaravone
    • 6.2.2. Riluzole
  • 6.3. Stem Cell Therapy

7. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies

8. Americas Amyotrophic Lateral Sclerosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyotrophic Lateral Sclerosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AB Science SA
  • 2. Amylyx Pharmaceuticals Inc.
  • 3. Aquestive Therapeutics Inc.
  • 4. Ascend Pharmaceuticals LLC
  • 5. Biogen Inc.
  • 6. Biohaven Pharmaceutical Holding Co Ltd
  • 7. BrainStorm Cell Limited
  • 8. Corestem, Inc.
  • 9. Cytokinetics, Incorporated
  • 10. F. Hoffmann-La Roche AG
  • 11. Genervon Biopharmaceuticals, LLC
  • 12. Hackensack Meridian Health, Inc.
  • 13. Implicit Bioscience Ltd.
  • 14. Ionis Pharmaceuticals, Inc.
  • 15. ITF Pharma, Inc.
  • 16. Kringle Pharma, Inc.
  • 17. Mitsubishi Tanabe Pharma Corporation
  • 18. Orion Corporation
  • 19. Orphazyme A/S
  • 20. Otsuka Pharmaceutical Co., Ltd.
  • 21. Pfizer Inc.
  • 22. Sanofi-Aventis Groupe S.A.
  • 23. Sun Pharmaceutical Industries Ltd
  • 24. Treeway B.V.
Product Code: MRR-AD36CD897F1B

LIST OF FIGURES

  • FIGURE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!